SIC
BBIO icon

Salem Investment Counselors’s BridgeBio Pharma BBIO Stock Holding History

Salem Investment Counselors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373 Hold
5
– – ﹤0.01% 1198
2026
Q1 		$372 Buy
+5
New +$362 ﹤0.01% 1185

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Salem Investment Counselors's BBIO Position: Q2 2026 in Review

Salem Investment Counselors held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 5 shares worth $373. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Salem Investment Counselors first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Salem Investment Counselors held 5 shares of BridgeBio Pharma worth $373 as of Q2 2026.
  • Salem Investment Counselors left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1198 holding.
  • Salem Investment Counselors first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.